Genes related to cancer pathways were downregulated upon pembrolizumab treatment, including angiogenic factors for tumor vascularization (NRP2, PTN, VEGFC, ID4 and ESM1), proto-oncogenes (RET and MET), tumor cell growth and proliferation genes (SPARC, FGFR2, TNC, KLF5, EGFR, PDGFC, FGF5, FGF7, KLF5, S100A8, and S100A9) and tumor migration/invasion-related genes (CDH1, CLDN7, TNC, BCAR1, MMP12, TGFB2, TNS3, LAMB1, MMP1, and RAB25) (Figure 2F). The gene discussed is EGFR; the disease is cancer.